Clinical trials
Human Immunodeficiency Virus (HIV) Infection clinical trials
Below are recruiting human immunodeficiency virus (hiv) infection clinical trials, each written for real people, not researchers. We’re tracking 61 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05452564RecruitingPhase 2
Baricitinib to help reduce HIV in the brain
This Phase 2 study tests baricitinib to see if it can lower HIV activity in the brain (CNS) for people already on stable HIV treatment. If you have well-controlled HIV in your blood, this trial looks for additional benefit inside the nervous system.
Atlanta, GeorgiaAges 18–65 - NCT04375800RecruitingPhase 2
Doravirine for children with HIV infection and stable treatment
This Phase 2 study tests doravirine (a type of HIV medicine) in children with HIV who are about 4 weeks to under 12 years old and weigh under 45 kg. It aims to see whether this regimen can control the virus safely, and some children may continue into an extension if they benefit.
Aurora, ColoradoAges 4 weeks–11 years - NCT07497594Recruiting
Twice-yearly shots to prevent HIV
This trial tests a new HIV prevention medicine called lenacapavir, given as a shot every six months. It's for young people at risk of HIV who haven't used PrEP before or have had gaps in their PrEP use.
Manaus, AmazonasAges 16–30 - NCT07024641RecruitingPhase 1
Safety study of GIGA-2339 for chronic Hepatitis B
This study tests an experimental antibody (GIGA-2339) given as an infusion to people with chronic Hepatitis B. It aims to see if the drug is safe and how the body processes it, possibly helping to control the virus.
Chandler, ArizonaAges 18 years+ - NCT07519330RecruitingPhase 2
Testing HH-006 treatment for chronic hepatitis B
This study tests a new drug called HH-006 to see if it can help treat chronic hepatitis B infection. Participants will be grouped by their infection level, and the study checks whether the drug is safe and works to reduce the hepatitis B virus.
Chongqing, Chongqing MunicipalityAges 18–45 - NCT06205056RecruitingPhase 1
HIV vaccine safety and immune response test
This trial tests a new combination HIV vaccine in healthy adults to see if it is safe and produces an immune response. If you are at low risk for HIV, you may help researchers learn more about future prevention strategies.
KampalaAges 18–50 - NCT04958122RecruitingPhase 3
Antibiotic treatment trial for early syphilis
This Phase 3 study tests whether cefixime can treat primary, secondary, or early latent syphilis. It may help by offering another effective antibiotic option, including for some people who also have HIV (if well controlled).
Los Angeles, CaliforniaAges 18 years+ - NCT07428330Recruiting
HPV self-testing to improve cervical cancer screening for women with HIV
This trial compares two ways to help women with HIV get screened for cervical cancer: a clinic-based approach versus a combined clinic and community outreach program. You may be able to provide samples yourself at a clinic or at home to test for HPV, the virus that can cause cervical cancer.
KampalaAges 25–49 - NCT06684379RecruitingPhase 1/Phase 2
Two Doses of PRS CK STORM for Severe Viral Pneumonia
This study tests a new drug called PRS CK STORM to see if it can safely calm the body's overactive immune response (cytokine storm) in people with severe pneumonia from COVID-19, flu, or RSV who need oxygen. It aims to reduce inflammation and improve recovery.
Alcalá de Henares, MadridAges 18 years+ - NCT07668271RecruitingPhase 4
HPV 9-valent vaccine lot consistency trial for women
This trial tests whether different batches of the HPV 9-valent vaccine work consistently. It's for Chinese women aged 18 to 30 who have not had any HPV vaccine or abnormal cervical screening results.
Zhangping, FujianAges 18–30 - NCT07596888RecruitingPhase 1
Early safety study of experimental HIV treatment IAP-086-1
This is an early-stage trial testing a new experimental drug (IAP-086-1) in people with HIV who have their virus well-controlled on current medications. Researchers want to understand how safe the drug is and how the body handles it.
Chapel Hill, North CarolinaAges 18–70 - NCT07706686RecruitingPhase 1
Dengue challenge study in people with prior infection
This study tests how the body responds to a mild, lab-made dengue virus in people who have had dengue before. It looks at how the immune system reacts to a second infection, which may help improve future vaccines and treatments.
Bethesda, MarylandAges 18–50 - NCT05706116RecruitingPhase 1
Study gives worm eggs by mouth to healthy adults
This Phase 1 trial tests how safe and tolerated orally taken Trichuris trichiura (a type of intestinal worm) eggs are in healthy adults. It aims to help researchers understand early safety and study setup before any future treatments.
Washington D.C., District of ColumbiaAges 18–45 - NCT07393594Enrolling by invitation
Tracer study for kidney transplant monitoring
This study looks at a new blood test to help monitor the health of your transplanted kidney and check for early signs of rejection. The test will be done as part of your usual care after a kidney transplant.
Phoenix, ArizonaAges 18 years+ - NCT07582796RecruitingPhase 1/Phase 2
RSV Vaccine Study for Adults in China
This study tests a new vaccine to protect against RSV (a common respiratory virus that causes cold-like illness, especially serious in older adults). The vaccine is made in laboratory cell cultures and includes an immune-boosting ingredient. Researchers want to see if it's safe and if it helps your body fight RSV infection.
Zigong, SichuanAges 18 years+ - NCT03266653RecruitingPhase 2
T-cell therapy for stubborn Epstein-Barr virus after transplants
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
Los Angeles, CaliforniaAges 1 month–79 years - NCT07645287RecruitingPhase 2
New HIV Combination Therapy for People on Biktarvy
This study tests a new HIV medication (GS-3242) combined with lenacapavir against your current Biktarvy regimen. Both are all-oral treatments for people whose HIV is well-controlled.
Phoenix, ArizonaAges 18 years+ - NCT06908096RecruitingPhase 1
EBV nanoparticle vaccine study for healthy adults
This study tests two experimental vaccines against Epstein-Barr virus (EBV), the germ that causes mono. You may be able to join if you are a healthy adult aged 18–29 and haven't had an EBV vaccine before. The trial will check if the vaccines are safe and trigger an immune response.
Bethesda, MarylandAges 18–29 - NCT05418868RecruitingPhase 1
Long-acting cabotegravir injection safety in healthy adults
This Phase 1 study tests how the body handles a long-acting (slow-release) cabotegravir injection combined with a drug called hyaluronidase. It also checks safety and side effects in healthy adults to help future HIV-prevention or treatment plans.
Orlando, FloridaAges 18–55 - NCT05262010RecruitingPhase 3
HPV vaccine study for Chinese women, ages 9–45
This trial tests an 11-type HPV vaccine to prevent infection from multiple HPV strains. If you enroll, you’ll receive scheduled vaccine doses and have health and gynecologic check-ins to see how well the vaccine works and is tolerated.
Hechi, GuangxiAges 18–45 - NCT07682961RecruitingPhase 3
Study of new HIV injection vs. standard injectables
This phase 3 trial tests a new long-acting, injectable two-drug combination (lenacapavir + teropavimab + zinlirvimab) vs. another injectable combo (cabotegravir + rilpivirine) for people whose HIV is already well-controlled on daily oral meds. It aims to see if the new combo can keep the virus under control with fewer injections.
San Francisco, CaliforniaAges 18 years+ - NCT07683000RecruitingPhase 3
Study of three HIV drugs for adults with controlled HIV
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
Berkeley, MichiganAges 18 years+ - NCT05071079Recruiting
Study infects volunteers with a malaria germ to test treatment
This study gives healthy volunteers a controlled infection with a type of malaria (vivax) to see how the infection behaves and how well curative anti-malaria medicine works. It may help researchers better design and test future malaria vaccines and treatments.
BangkokAges 20–55 - NCT03258567RecruitingPhase 2
Nivolumab for EBV-related lymphomas and abnormal immune illnesses
This trial tests nivolumab (an immune therapy) for people with EBV-positive lymphoma or EBV-driven immune/lymph conditions. It may help shrink tumors or control the disease when standard treatments have not worked or are not suitable.
Bethesda, MarylandAges 12 years+
Hear when a new Human Immunodeficiency Virus (HIV) Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for human immunodeficiency virus (hiv) infection?
- Yes. Clin2 currently lists 61 recruiting human immunodeficiency virus (hiv) infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a human immunodeficiency virus (hiv) infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a human immunodeficiency virus (hiv) infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.